Home > Research > Publications & Outputs > Cyclin-dependent kinase 12, a novel drug target...

Electronic data

  • MainText-AAM

    Rights statement: The Author's Accepted Manuscript (the accepted version of the manuscript as submitted by the author) may only be posted 6 months after the paper is published, consistent with our self-archiving embargo. Please note that the Author’s Accepted Manuscript may not be released under a Creative Commons license. For Nature Research Terms of Reuse of archived manuscripts please see: http://www.nature.com/authors/policies/license.html#terms

    Accepted author manuscript, 6 MB, PDF-document

    Embargo ends: 25/01/19

    Available under license: None

Links

Text available via DOI:

View graph of relations

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

Research output: Contribution to journalJournal article

E-pub ahead of print
  • Susan Wyllie
  • Michael Thomas
  • Stephen Patterson
  • Sabrinia Crouch
  • Manu De Rycker
  • Rhiannon Lowe
  • Stephanie Gresham
  • Thomas D. Otto
  • Laste Stojanovski
  • Frederick R. C. Simeons
  • Sujatha Manthri
  • Lorna M. MacLean
  • Fabio Zuccotto
  • Nadine Homeyer
  • Hannah Pflaumer
  • Markus Boesche
  • Lalitha Sastry
  • Paul Connolly
  • Sebastian Albrecht
  • Matt Berriman
  • Gerard Drewes
  • David W. Gray
  • Sonja Ghidelli-Disse
  • Susan Dixon
  • Jose M. Fiandor
  • Paul G. Wyatt
  • Michael A. J. Ferguson
  • Alan H. Fairlamb
  • Timothy J. Miles
  • Kevin D. Read
  • Ian H. Gilbert
Close
<mark>Journal publication date</mark>25/07/2018
<mark>Journal</mark>Nature
Number of pages17
<mark>State</mark>E-pub ahead of print
Early online date25/07/18
<mark>Original language</mark>English

Abstract

Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for this disease. Here we describe the development of an anti-leishmanial drug-like chemical series based on a pyrazolopyrimidine scaffold. The leading compound from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochemical, pharmacokinetic and toxicological properties for further development, and has been declared a preclinical candidate. Detailed mode-of-action studies indicate that compounds from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.